DM1-MCC

CAS No. 1228105-53-0

DM1-MCC( MCC-DM1 )

Catalog No. M23403 CAS No. 1228105-53-0

DM1-MCC is an anticancer drug DM1 with an MCC linker.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 272 In Stock
10MG 408 In Stock
25MG 734 In Stock
50MG 1102 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    DM1-MCC
  • Note
    Research use only, not for human use.
  • Brief Description
    DM1-MCC is an anticancer drug DM1 with an MCC linker.
  • Description
    DM1-MCC is an anticancer drug DM1 with an MCC linker.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    MCC-DM1
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    Others
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1228105-53-0
  • Formula Weight
    975.54
  • Molecular Formula
    C47H63ClN4O14S
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    C[C@@H]1[C@@H]2C[C@](NC(O2)=O)(O)[C@H](OC)C=CC=C(C)CC3=CC(N(C)C(C[C@H](OC([C@@H](N(C(CCSC4CC(N(CC5CCC(C(O)=O)CC5)C4=O)=O)=O)C)C)=O)[C@@]6(C)[C@@H]1O6)=O)=C(Cl)C(OC)=C3
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Liu, Yazhong, Zhou, Fang, Sang, Hua,等. LC–MS/MS method for the simultaneous determination of Lys-MCC-DM1, MCC-DM1 and DM1 as potential intracellular catabolites of the antibody-drug conjugate trastuzumab emtansine (T-DM1)[J]. Journal of Pharmaceutical & Biomedical Analysis, 2017, 137:170-177.
molnova catalog
related products
  • Dihydrodehydrodiconi...

    Dihydrodehydrodiconiferyl alcohol-9′-O-β-d-glucopyranoside

  • WAY-298592

    WAY-298592 is a small molecule used for high-throughput assays.

  • Ingenol

    Ingenol mebutate is an effective treatment for actinic keratosis. 2. Formulating novel derivatives from Ingenol esters may be an innovative approach to develop new lead compounds to reactivate latent HIV.